Summary
Health Catalyst posted third quarter revenue of $39.4 million for the three months ended September 30, 2019, up 19.9 percent from $32.9 million in the prior-year quarter. Year-to-date revenue of $111.4 million was up 45.7 percent from $76.5 million. Technology made up 54 percent of quarterly revenue and professional services 46 percent. One accounting detail matters for the growth story: Medicity closed on June 29, 2018, so the nine-month figures carry a full nine months of Medicity revenue against roughly three months in the comparable period a year earlier. Management flags that this will slow reported growth rates in the second half of 2019 relative to the first half.
Profitability moved the other way. Loss from operations was $20.7 million in the quarter, compared with a loss of $16.5 million a year earlier, and net loss was $21.4 million against $16.9 million. Operating margin slipped to -52.6%, down from -50.2%. Diluted EPS was -$1.40 versus -$3.71, a comparison that benefits from the much larger share count after the July initial public offering. The nine-month picture is better: loss from operations of $41.2 million versus $47.2 million, net loss of $45.8 million versus $48.4 million, and year-to-date operating margin of -37.0% against -61.7%.
Non-GAAP measures show the same split. Adjusted EBITDA was negative $8.4 million for the quarter versus negative $11.3 million a year ago, and negative $20.9 million for the nine months versus negative $28.6 million. Total Adjusted Gross Margin was 54 percent against 50 percent. Adjusted Professional Services Gross Margin jumped to 37 percent from 29 percent on better utilization, while Adjusted Technology Gross Margin edged to 68 percent from 67 percent. GAAP operating expense growth was dominated by stock-based compensation, which rose sharply after the IPO. General and administrative expense climbed 96 percent, including a $3.5 million cumulative catch-up tied to two-tier stock options at the closing. Research and development expense rose 24 percent and sales and marketing 7 percent.
Cash flow and the balance sheet both improved with the IPO. Net cash used in operating activities was $5.5 million in the quarter against $5.9 million a year earlier, and $19.1 million for the nine months against $27.3 million. Capital expenditures were $0.6 million in the quarter versus $0.2 million, and $1.7 million year to date versus $0.8 million. Cash, cash equivalents and short-term investments totaled $241.4 million at September 30, 2019, following net IPO proceeds of $194.6 million. Deferred revenue stood at $39.6 million, and remaining performance obligations were $64.0 million. The company also carries the OrbiMed term loan arranged in February 2019, a facility of up to $80.0 million of which $50.0 million was drawn, with principal payments starting in 2023 and maturity in February 2024.
Guidance points to more growth alongside continuing losses. For the fourth quarter of 2019, management guides Adjusted EBITDA of negative $9.2 million to negative $7.2 million. For the full year 2019, it guides Adjusted EBITDA of negative $30.1 million to negative $28.1 million. Revenue guidance is also given for the fourth quarter and for the full fiscal year, but the company did not reconcile the Adjusted EBITDA outlook to net loss, citing items such as stock-based compensation that it cannot reasonably predict.
Several risks sit behind those numbers. Medicity customers have historically generated a lower dollar-based retention rate, and management expects flat to declining revenue from them. Cross-selling the platform into those accounts is still early. Customer additions may slow because health system procurement cycles are long. The migration of customers from on-premise and company data centers to Microsoft Azure raises hosting cost per customer and acts as a headwind to Adjusted Technology Gross Margin, and professional services margin could decline as headcount and service mix shift. The company also notes that its net operating loss carryforwards may be limited by ownership change rules, and that it may need capital it cannot raise on acceptable terms.
Forecast
Reported figures
GAAP, from SEC filings| Metric | Q3 FY2019 | Q2 FY2019 | QoQ | Q3 FY2018 | YoY |
|---|---|---|---|---|---|
| Revenue | $39.4M | $36.8M | +7.1% | — | — |
| Research & development | $13.5M | $9.7M | +38.8% | — | — |
| Sales & marketing | $14.7M | $10.4M | +41.8% | — | — |
| General & administrative | $11.0M | $6.1M | +79.2% | — | — |
| Total operating expenses | $41.5M | $28.5M | +45.9% | — | — |
| Operating income (loss) | -$20.7M | -$9.4M | -121.5% | — | — |
| Operating margin | -52.6% | -25.4% | -27.2 pp | — | — |
| Net income (loss) | -$21.4M | -$10.7M | -100.3% | — | — |
| Net margin | -54.3% | -29.1% | -25.3 pp | — | — |
Risks
The healthcare analytics market is intensely competitive, including from industry-agnostic analytics companies and EHR vendors such as Epic Systems and Cerner, and larger competitors such as Optum Analytics and IBM. Increased competition is likely to result in pricing pressures that could negatively impact sales, profitability, or market share.
The sales cycle for a new customer has averaged 11 months and in some cases exceeded 24 months. MD&A adds that customers are large, complex organizations with long procurement cycles, which may lead to declines in the pace of new customer additions.
The data platform depends on sourcing data from multiple third-party clinical, financial, and operational systems. Vendors may engage in information blocking, and the March 3, 2019 Proposed Rule under the 21st Century Cures Act may not be finalized or may be modified or not observed, which could limit data access and impair the Solution.
The DOS platform and analytics applications rely on third-party infrastructure including Microsoft Azure and Flexential. MD&A expects the Microsoft Azure transition to increase cost of technology revenue and provide a headwind against increases in Adjusted Technology Gross Margin, with planned transitions substantially complete by the end of 2020.
The June 2018 Medicity acquisition requires integration and cross-selling, and MD&A states that Medicity customers historically generated a lower Dollar-based Retention Rate and expects flat to declining revenue from Medicity customers in the foreseeable future.
A significant portion of revenue is expected from renewal of existing customer contracts and additional sales. Many subscription contracts have initial terms of one to three years, most customers have no obligation to renew, and certain contracts are terminable for convenience or after repeated service-level failures.
Healthcare laws and regulations are rapidly evolving, including uncertainty around the ACA following the December 14, 2018 U.S. District Court ruling. Privacy and data protection laws, AHRQ certification requirements, and anti-information blocking enforcement could increase compliance costs, restrict offerings, or lead to liability.
The company incurred a net loss of $45.8 million for the nine months ended September 30, 2019. It expects costs to increase as it invests to grow the business and may need to raise additional capital through equity or debt financings.
The OrbiMed Credit Facility is an $80.0 million senior term loan secured by substantially all assets, including intellectual property, with restrictive covenants and a February 6, 2024 maturity. A default could allow the lender to declare all obligations immediately due and payable and take control of pledged assets.
Analytics services may be used to support clinical decision-making and treatment plans. If applications, content, or services are associated with faulty clinical decisions, incomplete analyses, or errors, the company could face product liability, medical malpractice, or other claims, including claims for death, and insurance may be inadequate.
The three largest customers comprised 4.8%, 3.7%, and 3.7% of revenue, or 12.2% in the aggregate, for the nine months ended September 30, 2019, compared with 6.6%, 6.0%, and 4.7%, or 17.3% in the aggregate, for the nine months ended September 30, 2018. The loss, termination, or renegotiation of any largest customer contract could negatively impact results.
Competition for senior sales executives, software engineers, and experienced analytics personnel is intense. The filing also notes that several senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints, and co-founder Steven Barlow has been on a leave of absence to serve a full-time mission that will likely extend until August 2020.
The company began introducing new pricing for its Solution to new customers in the fourth quarter of 2018 and may need to continue adjusting its pricing model. Its assessments may be inaccurate, and it could underprice or overprice the Solution, harming results and predictability.
The company requires customers to provide necessary notices, permissions, and waivers for use and disclosure of information. If customers fail to do so, use of data may be restricted and the company could face claims, civil or criminal liability, or government investigations.
As of September 30, 2019, there were 36,472,223 shares of common stock outstanding and 7,923,437 options outstanding. Lock-up and market standoff agreements expire 180 days after the IPO, and future equity issuances could dilute stockholders and cause the market price to decline.
Following the July 29, 2019 IPO, the company expects additional costs for compliance, reporting, insurance, investor relations, and corporate governance. These requirements may strain resources, divert management attention, and make it more difficult to attract and retain qualified board members and executives.
SaaS KPIs
All quarters →Adjusted EBITDA
Adjusted Professional Services Gross Margin
Adjusted Technology Gross Margin
Total Adjusted Gross Margin
Adjusted Professional Services Gross Profit
Adjusted Technology Gross Profit
Total Adjusted Gross Profit
Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q3 FY2019 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.